In Vivo Imaging of Pigmentary Disorders by Reflectance Confocal Microscopy
NCT ID: NCT00771355
Last Updated: 2011-03-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
40 participants
OBSERVATIONAL
2008-08-31
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Subjects with vitiligo.
No interventions assigned to this group
2
Subjects with melasma.
No interventions assigned to this group
3
Subjects with post-inflammatory hyper-pigmentation.
No interventions assigned to this group
4
Subjects with post-inflammatory hypo-pigmentation.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Clinical diagnosis of vitiligo, melasma, post-inflammatory hypo or depigmentation or post-inflammatory hyperpigmentation.
3. Willing and able to understand and sign informed consent.
4. Able to complete study and comply with study procedures.
Exclusion Criteria
2. Use of light therapy such as narrow-band-UVB, PUVA or laser within the past 2 months.
3. Intake of medications that can cause pigmentary changes within the past year. Examples are:
* Antimalarials (chloroquine, hydroxychloroquine)
* Chemotherapeutics (bleomycin, busulfan, doxorubicin, daunorubicin, fluorouracil, cyclophosphamide, and carmustine)
* Heavy metals (gold, silver, bismuth, and mercury)
* Tetracyclines (including minocycline, doxycycline)
* Amiodarone
* Azidothymidine
* Clofazimine
4. Clinically significant abnormal findings or conditions (other than the pigmentary disorder), which might, in the opinion of the Principal Investigator, interfere with study evaluations or pose a risk to subject safety during the study.
5. Subjects who are known to be pregnant or planning a pregnancy.
20 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Massachusetts General Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ernesto Gonzalez, MD
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Unit for Research Trials in Skin
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rajadhyaksha M, Grossman M, Esterowitz D, Webb RH, Anderson RR. In vivo confocal scanning laser microscopy of human skin: melanin provides strong contrast. J Invest Dermatol. 1995 Jun;104(6):946-52. doi: 10.1111/1523-1747.ep12606215.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-P-001137/1
Identifier Type: -
Identifier Source: org_study_id